You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

340 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Epcoritamab (Outpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma
High Cost Therapy Funding Program
    Epcoritamab (Inpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Guidelines and Advice
Status: Current
ID: GL 19-7
Mar 2024
This is FR page
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Funding:
ODB - General Benefit
    filgrastim (biosimilars) - refer to ODB Formulary for details
Nov 2025
Drug
Other Name(s): Epkinly™
Nov 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative

Pages